Elanco Animal Health (ELAN) said Tuesday it was partnering with MedGene to help commercialize the company's vaccine to help prevent avian influenza in dairy cattle.
Medgene previously met all of the US Department of Agriculture's requirements for its bovine vaccine platform technology, which is now in the final stages of review ahead of an expected conditional license approval, the companies said.
The prior USDA authorization also allowed Medgene to accelerate development of its H5N1 vaccine as well as adapting its existing vaccine manufacturing to protect the US dairy herd, the companies said.
Elanco shares were falling over 7% in early Tuesday trading after the company reported Q4 earnings that missed Wall Street expectations and also guided 2025 results below analyst consensus calls.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.